Last checked at 18 Aug 2022 07:00
18 August 2022
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Appointment of Chief Financial Officer
The Board of Proteome Sciences plc is pleased to announce that Abdelghani Omari has been appointed as the Company's new Chief Financial Officer. He will take up the position on September 1st, 2022 and will become a director of the Company.
Abdel joins Proteome Sciences from Paion AG, a listed speciality pharmaceutical company, where he has been CFO and since 2014 a member of the management board. During his time at Paion he has negotiated numerous license agreements with pharma companies and has raised more than 150 million Euros in financing from investors in the U.S. and in Europe. In addition to the finance role, Abdel was also responsible for HR, IT, Legal, IP & Compliance and more recently investor relations. Abdel has more than 20 years' experience in finance, starting his career at KPMG Audit after a business degree from the University of Aachen. At KPMG he worked in audit and financial consultancy roles prior to joining Paion.
Proteome Sciences' Chief Executive Officer, Dr Mariola Soehngen, commented "The Board and the Company welcome Abdel as Proteome Sciences' CFO at this important point in the company's growth. Abdel brings a wealth of relevant experience to the team as we pursue the Company´s strategy of organic growth, to grow the business through adding new high value services to our portfolio and enter into further internationalisation of the business.
Commenting on his appointment, Abdel said "I am very excited to join Proteome Sciences at this stage. The Company has a unique technology and highly skilled and committed people. Proteome Sciences has an exciting journey ahead and I am pleased to be joining the Company as we shape and accelerate its future growth."
As part of Mr Omari's remuneration package, three months after his appointment he will be granted 4,000,000 options under the Company's share option scheme ("Options"). The Options will be exercisable at the market price on the day of award per Option and will vest in three equal annual tranches on 1 September 2023, 1 September 2024 and 1 September 2025. Each Option is exercisable into one Ordinary Share and once vested, can be exercised up until the 10th anniversary.
Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Mr Abdelghani Omari (aged 45) has held the following directorships or partnerships in the past five years:
Current | Previous |
Paion AG, Germany, Pharma Paion Holdings UK Ltd, UK Paion UK Ltd, UK TheraSci Ltd, UK Paion Netherlands B.V. | Paion Inc, USA Paion Scandic, Aps, Denmark
|
There is no further information on Abdelghani Omari required to be disclosed under Schedule Two, paragraph (g) of the AIM Rules for Companies.
For further information:
Proteome Sciences plc | |
Proteome Sciences plc | |
Dr Mariola Soehngen, Chief Executive Officer | Tel: +44 (0)20 7043 2116 |
Dr Ian Pike, Chief Scientific Officer | |
Richard Dennis, Chief Commercial Officer | |
Allenby Capital Limited (AIM Nominated Adviser & Broker) | |
John Depasquale / Jeremy Porter (Corporate Finance) Tony Quirke (Sales) | Tel: +44 (0) 20 3328 5656 |
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.
The Company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany.